Susquehanna International Group’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-340,086
| Closed | -$13.7M | – | 13333 |
|
|
2026
Q1 | $13.7M | Sell |
340,086
-193,823
| -36% | -$4.18M | ﹤0.01% | 2675 |
|
|
2025
Q4 | $13.4M | Buy |
533,909
+220,025
| +70% | +$5.16M | ﹤0.01% | 2681 |
|
|
2025
Q3 | $7.1M | Sell |
313,884
-14,842
| -5% | -$346K | ﹤0.01% | 3538 |
|
|
2025
Q2 | $5.69M | Buy |
328,726
+299,221
| +1,014% | +$5.54M | ﹤0.01% | 3735 |
|
|
2025
Q1 | $645K | Buy |
29,505
+3,288
| +13% | +$90.8K | ﹤0.01% | 8338 |
|
|
2024
Q4 | $837K | Sell |
26,217
-145,575
| -85% | -$4.38M | ﹤0.01% | 7415 |
|
|
2024
Q3 | $4.95M | Sell |
171,792
-307,171
| -64% | -$11.4M | ﹤0.01% | 3601 |
|
|
2024
Q2 | $18.4M | Buy |
478,963
+234,702
| +96% | +$10.6M | ﹤0.01% | 1817 |
|
|
2024
Q1 | $14.4M | Sell |
244,261
-138,571
| -36% | -$8.83M | ﹤0.01% | 2154 |
|
|
2023
Q4 | $22.9M | Buy |
382,832
+10,047
| +3% | +$510K | ﹤0.01% | 1664 |
|
|
2023
Q3 | $14.2M | Buy |
372,785
+56,875
| +18% | +$2.5M | ﹤0.01% | 2135 |
|
|
2023
Q2 | $28.8M | Buy |
315,910
+234,114
| +286% | +$20.2M | 0.01% | 1397 |
|
|
2023
Q1 | $5.4M | Buy |
81,796
+50,064
| +158% | +$2.89M | ﹤0.01% | 3357 |
|
|
2022
Q4 | $1.64M | Sell |
31,732
-26,128
| -45% | -$1.39M | ﹤0.01% | 5090 |
|
|
2022
Q3 | $3.95M | Buy |
57,860
+4,080
| +8% | +$241K | ﹤0.01% | 3536 |
|
|
2022
Q2 | $2.43M | Sell |
53,780
-21,855
| -29% | -$996K | ﹤0.01% | 4493 |
|
|
2022
Q1 | $3.84M | Buy |
75,635
+6,886
| +10% | +$304K | ﹤0.01% | 4149 |
|
|
2021
Q4 | $3.25M | Sell |
68,749
-40,661
| -37% | -$1.6M | ﹤0.01% | 4506 |
|
|
2021
Q3 | $3.61M | Buy |
109,410
+80,641
| +280% | +$4.53M | ﹤0.01% | 4573 |
|
|
2021
Q2 | $1.82M | Buy |
28,769
+2,846
| +11% | +$147K | ﹤0.01% | 6138 |
|
|
2021
Q1 | $1.11M | Buy |
25,923
+12,183
| +89% | +$576K | ﹤0.01% | 7461 |
|
|
2020
Q4 | $786K | Sell |
13,740
-29,103
| -68% | -$1.23M | ﹤0.01% | 7258 |
|
|
2020
Q3 | $1.29M | Sell |
42,843
-45,818
| -52% | -$1.37M | ﹤0.01% | 5512 |
|
|
2020
Q2 | $2.9M | Sell |
88,661
-37,133
| -30% | -$1.19M | ﹤0.01% | 3862 |
|
|
2020
Q1 | $3.37M | Sell |
125,794
-5,538
| -4% | -$197K | ﹤0.01% | 3112 |
|
|
2019
Q4 | $4.02M | Buy |
131,332
+68,034
| +107% | +$1.88M | ﹤0.01% | 3283 |
|
|
2019
Q3 | $1.52M | Buy |
63,298
+28,322
| +81% | +$780K | ﹤0.01% | 4779 |
|
|
2019
Q2 | $886K | Buy |
+34,976
| New | +$712K | ﹤0.01% | 5944 |
|
Other funds holding APLS
Susquehanna International Group's APLS Position: Q2 2026 in Review
Susquehanna International Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 340,086 shares — an estimated $13.7M sold.
Susquehanna International Group first reported a position in APLS in Q2 2019 and held it in 28 quarters. The position peaked at $28.8M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Susquehanna International Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Susquehanna International Group sold 340,086 Apellis Pharmaceuticals shares in Q2 2026, an estimated $13.7M.
- Susquehanna International Group first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 28 quarters.
- Susquehanna International Group's Apellis Pharmaceuticals position peaked at $28.8M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.